Rate of Conversion from Prodromal Alzheimer's Disease to Alzheimer's Dementia: A Systematic Review of the Literature
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Background: The purpose of this study was to summarize published estimates for conversion from mild cognitive impairment or amnestic mild cognitive impairment to Alzheimer's dementia. We carried out a systematic review of English language publications to identify cohort studies published since January 2006 that reported the risk or rate of conversion. Summary: Thirty-two cohort studies were identified, of which 14 reported annualized conversion rates (ACRs). Conversions over 1 year ranged from 10.2 to 33.6% (5 studies, median: 19.0%), and over 2 years from 9.8 to 36.3% (7 studies, median: 18.6%). ACRs ranged from 7.5 to 16.5% (7 studies, median: 11.0%) per person-year for studies recruiting from clinics, and from 5.4 to 11.5% (7 studies, median: 7.1%) for community samples. Key Message: Extensive variation was observed in conversion rates due to the population sampled, diagnostic criteria, and duration, and because many studies did not account for loss to follow-up.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“About one-third develop dementia due to Alzheimer's within five years.52”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“About one‐third develop dementia due to Alzheimer's within five years.”
From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [52]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946
Current concepts in mild cognitive impairment
Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., Ritchie, K., Rossor, M., Thal, L., & Winblad, B. (2001) · Archives of Neurology · doi:10.1001/archneur.58.12.1985 · Cited by 4,781
Forecasting the global burden of Alzheimer's disease
Brookmeyer, R., Johnson, E., Ziegler‐Graham, K., & Arrighi, H. M. (2007) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2007.04.381 · Cited by 3,370
Self-citation
Cited by
Items 101–200 of 427
Cognitive Decline in Alzheimer’s Disease
Testo, A. A., Roundy, G., & Dumas, J. A. (2024) · Current topics in behavioral neurosciences · doi:10.1007/7854_2024_527 · Cited by 47
Nasrouei, S., Rattel, J. A., Liedlgruber, M., Marksteiner, J., & Wilhelm, F. H. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.11.003 · Cited by 30
Liu, N., Zhang, T., Ma, L., Wei, W., Li, Z., Jiang, X., Sun, J., Pei, H., & Li, H. (2021) · Advances in Nutrition · doi:10.1093/advances/nmab074 · Cited by 31
Dabiri, S., Mwendwa, D. T., & Campbell, A. L. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.11.034 · Cited by 36
Taha, H. B. (2025) · npj Dementia · doi:10.1038/s44400-024-00002-y · Cited by 34
Mazzeo, S., Santangelo, R., Bernasconi, M. P., Cecchetti, G., Fiorino, A., Pinto, P., Passerini, G., Falautano, M., Comı, G., & Magnani, G. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160360 · Cited by 31
Joung, K.-I., Kim, S., Cho, Y. H., & Cho, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-43066-0 · Cited by 32
Kinoshita, K., Otsuka, R., Takada, M., Tsukamoto‐Yasui, M., Nishita, Y., Tange, C., Tomida, M., Shimokata, H., Kuzuya, M., Imaizumi, A., et al. (2020) · The journal of nutrition health & aging · doi:10.1007/s12603-020-1470-9 · Cited by 34
Advances in Multimodal Behavioral Analytics for Early Dementia Diagnosis: A Review
Guruge, C. J. P., Oviatt, S. L., Haghighi, P. D., & Pritchard, E. (2021) · INTERNATIONAL CONFERENCE ON MULTIMODAL INTERACTION · doi:10.1145/3462244.3479933 · Cited by 43
“Approximately 32% 38% of people with MCI eventually develop AD [4], [5].”
BackgroundStone, D. B., Ryman, S. G., Hartman, A. P., Wertz, C. J., Vakhtin, A. A., & Initiative, A. D. N. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.711579 · Cited by 28
“clinically defined as mild cognitive impairment (MCI); however, it is estimated that only 32–38% of elderly patients exhibiting MCI will develop AD (Mitchell and Shiri-Feshki, 2009; Ward et al., 2013).”
BackgroundAdvances in Resting State Neuroimaging of Mild Cognitive Impairment
Li, L., Xing, G., & Han, Y. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00671 · Cited by 31
Papadatos, Z., & Phillips, N. A. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2023.04.001 · Cited by 35
Alzheimer’s Disease Etiology Hypotheses and Therapeutic Strategies: A Perspective
Scarano, N., Musumeci, F., Casini, B., Brullo, C., D’Ursi, P., Fossa, P., Schenone, S., & Cichero, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146980 · Cited by 38
“Among MCI patients, about one-third develop Alzheimer’s dementia within five years [16]: 26% of MCI patients, instead, were shown to revert to normal conditions [17].”
Predicting Conversion from MCI to AD Combining Multi-Modality Data and Based on Molecular Subtype
Li, H.-T., Yuan, S.-X., Wu, J.-S., Gu, Y., & Sun, X. (2021) · Brain Sciences · doi:10.3390/brainsci11060674 · Cited by 27
“It is worth mentioning that not all people with MCI or in other preclinical stages of Alzheimer’s disease will develop AD [4].”
BackgroundA short perspective on the long road to effective treatments for Alzheimer's disease
Reynolds, D. S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14581 · Cited by 29
RNN-Based Alzheimer's Disease Prediction from Prodromal Stage using Diffusion Tensor Imaging
Velazquez, M., Anantharaman, R., Velazquez, S., & Lee, Y. (2019) · IEEE International Conference on Bioinformatics and Biomedicine · doi:10.1109/bibm47256.2019.8983391 · Cited by 21
“On average, 32 percent of individuals with Mild Cognitive Impairment will develop Alzheimer’s Disease within the next 5 years of their follow-up appointments[16].”
BackgroundBermejo‐Pareja, F., Contador, I., del Ser, T., Olazarán, J., Velasco, S. L., Vega, S., & Benito‐León, J. (2020) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5474 · Cited by 31
Yang, Z., Zhang, W., Liu, D., Zhang, S., Tang, Y. P., Song, J., Long, J., Yang, J., Jiang, H., Li, Y., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.910261 · Cited by 30
Bray, N. W., Pieruccini‐Faria, F., Witt, S. T., Rockwood, K. J., Bartha, R., Doherty, T. J., Nagamatsu, L. S., Almeida, Q. J., Liu-Ambrose, T. Y. L., Middleton, L. E., et al. (2022) · GeroScience · doi:10.1007/s11357-022-00702-4 · Cited by 29
Domínguez-Chávez, C. J., Murrock, C. J., Guerrero, P. I. C., & Salazar-González, B. C. (2019) · Geriatric Nursing · doi:10.1016/j.gerinurse.2019.06.004 · Cited by 38
Collazos-Huertas, D. F., Peña, D. A. C., & Castellanos-Dominguez, G. (2018) · International Journal of Neural Systems · doi:10.1142/s0129065718500429 · Cited by 26
Initiative, A. D. N., Bhasin, H., & Agrawal, R. K. (2020) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-020-1055-x · Cited by 27
Galvin, J. E., Chrisphonte, S., & Chang, L. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215020 · Cited by 28
“Cognitive decline may be first detected clinically as mild cognitive impairment (MCI) with approximately 32% of MCI patients going on to develop ADRD within 5 years [4].”
Gut Microbiota and Targeted Biomarkers Analysis in Patients With Cognitive Impairment
Lu, S., Yang, Y., Xu, Q., Wang, S., Yu, J. Z., Zhang, B., Wang, Z., Zhang, Y., Lu, W., & Hong, K. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.834403 · Cited by 27
Bray, N. W., Pieruccini‐Faria, F., Witt, S. T., Bartha, R., Doherty, T. J., Nagamatsu, L. S., Almeida, Q. J., Liu-Ambrose, T. Y. L., Middleton, L. E., Bherer, L., et al. (2023) · GeroScience · doi:10.1007/s11357-023-00805-6 · Cited by 29
“Brain health deteriorates with aging [1–4], but it occurs much more rapidly in those with mild cognitive impairment (MCI) [5, 6], a prodromal state between healthy cognitive aging and dementia syndromes, including Alzheimer’s disease [7, 8].”
BackgroundLiu, M., Xie, X., Xie, J., Tian, S., Du, X., Feng, H., & Zhang, H. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1192562 · Cited by 25
“Mild cognitive impairment is often considered to be a precursor stage of AD, and epidemiological surveys show that approximately 10 to 15% of patients with MCI develop AD every year, which is significantly higher than the 1 to 2% conversion rate of AD in normal aging (6).”
BackgroundLi, K., Wu, J., Mei, Y., Zhao, J., Zhou, Q., Li, Y., Yang, M., Xu, J., Zhao, M., & Xu, Q. (2023) · Chemosphere · doi:10.1016/j.chemosphere.2023.140049 · Cited by 24
The age-specific comorbidity burden of mild cognitive impairment: a US claims database study
Li, G., Toschi, N., Devanarayan, V., Batrla, R., Boccato, T., Cho, M., Ferrante, M., Frech, F. H., Galvin, J. E., Henley, D. B., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01358-8 · Cited by 31
“For individuals with MCI, the likelihood of progression to any form of dementia is estimated to occur at a rate three to five times higher than among those without MCI [2–5].”
BackgroundKannan, L., Bhatt, T. S., & Ajilore, O. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1041434 · Cited by 25
Nezhadmoghadam, F., Martínez‐Torteya, A., Treviño, V., Martínez-Ledesma, E., Santos‐Díaz, A., Tamez‐Peña, J. G., & Initiative, A. D. N. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666210831145825 · Cited by 25
Yoong, S. Q., Lu, J., Xing, H., Gyanwali, B., Tan, Y., & Wu, X. V. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101491 · Cited by 24
Fairchild, J. K., MYERS, J. N., Louras, P., Jo, B., McNerney, M. W., Hallmayer, J. F., & Yesavage, J. A. (2023) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2023.12.002 · Cited by 27
Socially Assistive Robots for patients with Alzheimer's Disease: A scoping review
Karami, V., Yaffe⃰, M. J., Gore, G. C., Moon, A., & Rahimi, S. A. (2024) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2024.105409 · Cited by 34
Aljuhani, M., Ashraf, A., & Edison, P. (2024) · Brain Communications · doi:10.1093/braincomms/fcae435 · Cited by 26
Ma, X., Xie, Z., Wang, H., Tian, Z., Bi, Y., Li, Y., & Zhang, L. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1101950 · Cited by 28
“It is estimated that 32% of MCI patients will develop AD within the next 5 years (Ward et al., 2013).”
BackgroundExploring small non-coding RNAs as blood-based biomarkers to predict Alzheimer’s disease
Gutiérrez-Tordera, L., Papandreou, C., Novau-Ferré, N., García‐González, P., Rojas, M., Marquié, M., Chapado, L. A., Papagiannopoulos, C. K., Fernàndez‐Castillo, N., Valero, S., et al. (2024) · Cell & Bioscience · doi:10.1186/s13578-023-01190-5 · Cited by 21
“Third, considering that 15% of MCI participants develop AD after 2 years [69] and about 33% within 5 years [70], incorporating a longer follow-up period would strengthen the predictive value of the sncRNA signatures.”
BackgroundAlzheimer’s disease is an inherent, natural part of human brain aging: an integrated perspective
Ferrer, I. (2022) · Free Neuropathology · doi:10.17879/freeneuropathology-2022-3806 · Cited by 30
Hwang, H., Tseng, K.-C., Chen, S., Yu, W., Chen, C.-Y., & Lin, M. (2023) · Aging & Mental Health · doi:10.1080/13607863.2023.2225430 · Cited by 26
“The incidence of dementia is higher among older adults with MCI, with an annual rate of 5%~12% in those residing in the community and 8%~17% in those in specialty clinics, compared to 1%~2% in the general population (Farias et al., 2009; Ward et al., 2013).”
BackgroundLin, J., Pathak, J. L., Shen, Y. S., Mashrah, M. A., Zhong, X., Chen, J., Li, Z., Xia, J., Liang, Y., & Zeng, Y. (2023) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000535776 · Cited by 23
“A systematic review found that 19% of patients with MCI would convert to AD within 1 year [3].”
BackgroundMild cognitive impairment—not always what it seems
Richard, E., & Brayne, C. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.23 · Cited by 23
Ma, Y., Sun, W., Bai, J., Gao, F., Ma, H., Liu, H., Hu, J., Xu, C., Zhang, X., Liu, Z., et al. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14613 · Cited by 24
Li, K., Ye, H., Dong, Z., Amujilite, Zhao, M., Xu, Q., & Xu, J. (2024) · Environmental Research · doi:10.1016/j.envres.2024.119506 · Cited by 20
Zheng, W., Yao, Z., Li, Y., Zhang, Y., Hu, B., Wu, D., & Initiative, A. D. N. (2019) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2019.00399 · Cited by 20
Gao, H.-B., Zhao, S.-Y., Gu, Z., Wang, X., Zhao, R., Pan, Z., Li, H., Lü, F., & Shen, M. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107411 · Cited by 21
Formica, C., Bonanno, L., Giambò, F. M., Maresca, G., Latella, D., Marra, A., Cucinotta, F., Bonanno, C., Lombardo, M., Tomarchio, O., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13091386 · Cited by 22
“About 15% of MCI patients develop dementia after two years, [14] while one third develop AD within five years [15].”
BackgroundCascella, M., & Khalili, Y. A. (2019) · StatPearls · Cited by 18
Luo, H., Wu, B., González, H. M., Stickel, A. M., Kaste, L. M., Tarraf, W., Daviglus, M. L., Sanders, A. E., & Cai, J. (2022) · The Journals of Gerontology Series A · doi:10.1093/gerona/glac178 · Cited by 21
Rao, S. M., Galioto, R., Sokolowski, M., Pierce, M., Penn, L., Sturtevant, A., Skugor, B., Anstead, B., Leverenz, J. B., Schindler, D., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220929 · Cited by 18
“Although MCI can occur for reasons other than AD and some MCI patients remain stable or revert to normal cognition, approximately 32–38% of MCI patients convert to dementia within a 5-year follow-up [2, 3].”
BackgroundA novel speech analysis algorithm to detect cognitive impairment in a Spanish population
Kaser, A. N., Lacritz, L. H., Winiarski, H. R., Gabirondo, P., Schaffert, J., Coca, A. J., Jiménez-Raboso, J., Rojo, T., Zaldua, C., Honorato, I., et al. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1342907 · Cited by 21
Santabárbara, J., Gracia‐García, P., Pírez, G., López‐Antón, R., de la Cámara, C., Ventura, T., Pérez-Sastre, M., Lobo, E., Saz, P., Marcos, G., et al. (2016) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2016.07.005 · Cited by 20
Neurocognitive aging and cognitive disorders
Tabeeva, G. R. (2019) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro2019119061160 · Cited by 41
Meditation treatment of Alzheimer disease and mild cognitive impairment
Chen, Y., Zhang, J., Zhang, T., Cao, L., You, Y., Zhang, C., Liu, X., & Zhang, Q. (2020) · Medicine · doi:10.1097/md.0000000000019313 · Cited by 18
Lella, E., & Vessio, G. (2020) · Pattern Recognition Letters · doi:10.1016/j.patrec.2020.06.001 · Cited by 19
“Nevertheless, according to some studies reported in literature, e.g. (Ward et al., 2013; Vos et al., 2015), people with MCI are at a higher risk of developing Alzheimer’s disease (AD), or other kinds of dementia, than people without MCI.”
ResultGeladó, S., Gómez‐Ruiz, I., & Diéguez-Vide, F. (2021) · Journal of Neurolinguistics · doi:10.1016/j.jneuroling.2021.101038 · Cited by 17
Meta-analysis of the association between dietary inflammatory index and cognitive health
Ding, T., Aimaiti, M., Cui, S., Shen, J., Lu, M., Wang, L., & Bian, D. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1104255 · Cited by 20
From Mild Cognitive Impairment to Dementia: The Impact of Comorbid Conditions on Disease Conversion
Menegon, F., Marchi, F. D., Aprile, D., Zanelli, I., Decaroli, G., Comi, C., & Tondo, G. (2024) · Biomedicines · doi:10.3390/biomedicines12081675 · Cited by 23
“About 10–20% of individuals with MCI annually convert to dementia; thus, a considerable proportion of these individuals will ultimately convert to dementia over 2–5 years [8–11].”
Nesset, M., Kersten, H., & Ulstein, I. D. (2014) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000363734 · Cited by 20
MCI Detection Using Kernel Eigen-Relative-Power Features of EEG Signals
Hsiao, Y.-T., Tsai, C.-F., Wu, C., Trinh, T.-T., Lee, C., & Liu, Y. (2021) · Actuators · doi:10.3390/act10070152 · Cited by 17
“Among individuals aged 65 years or older, the conversion rate from MCI to AD is 15% within 2 years [3] and 32% within 5 years [4] after the first diagnosis of MCI.”
Performance of Validated MicroRNA Biomarkers for Alzheimer’s Disease in Mild Cognitive Impairment
Sandau, U. S., Wiedrick, J. T., Smith, S. J., McFarland, T. J., Lusardi, T. A., Lind, B., Harrington, C. A., Lapidus, J., Galasko, D. R., Quinn, J. F., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200396 · Cited by 22
Li, F., Yan, Y., Zheng, L., Wang, C., Guan, X., Hong, S., & Guo, H. (2023) · BMC Geriatrics · doi:10.1186/s12877-023-03761-0 · Cited by 19
“Although MCI may revert back to a normal cognitive state, about one-third MCI patients develop Alzheimer’s disease (AD) within 5 years [2].”
BackgroundPark, M., Ahn, J., Kim, Y.-J., Lee, J., Lee, J.-C., Hwang, S., & Kim, K. (2024) · Cells · doi:10.3390/cells13131085 · Cited by 19
“Consequently, the early detection of MCI patients at elevated risk for AD conversion is imperative for optimizing therapeutic interventions, particularly in the context of anti-A β therapy [3,5–7].”
BackgroundAnimal Research for Alzheimer Disease: Failures of Science and Ethics
Pippin, J. J., Cavanaugh, S. E., & Pistollato, F. (2019) · BRILL eBooks · doi:10.1163/9789004391192_021 · Cited by 17
“fraught with low specificity and positive predictive value (Mitchell and Shiri Feshki, 2009; Richard and Brayne, 2014; Roberts et al., 2014a; Ward et al., 2013).”
Arruda, J. E., McInnis, M. C., & Steele, J. (2020) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2020.05.012 · Cited by 16
der Linden, M. V., & der Linden, A. J. V. (2016) · Dementia · doi:10.1177/1471301216657270 · Cited by 20
Pyun, J., Ryoo, N., Park, Y. H., & Kim, S. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00749-5 · Cited by 17
Zeng, J., Hu, K., Wang, Z., Huang, Y.-C., Zhang, Y., Peng, H., & Ma, S. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00086 · Cited by 20
The association between cognitive impairment and breast and colorectal cancer screening utilization
Yang, S. C., Bian, J., George, T. J., Daily, K. C., Zhang, D., Braithwaite, D., & Guo, Y. M. (2021) · BMC Cancer · doi:10.1186/s12885-021-08321-6 · Cited by 16
“Studies show that about one in three individuals with cognitive impairment will develop ADRD in 5 years [10].”
BackgroundLi, W., Zhao, Z., Liu, M., Yan, S., An, Y., Qiao, L., Wang, G., Qi, Z., & Lu, J. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215338 · Cited by 16
Application of artificial intelligence in Alzheimer’s disease: a bibliometric analysis
Song, S., Li, T., Lin, W., Liu, R., & Zhang, Y. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1511350 · Cited by 20
Hessler, J. B., Tucha, O. M., Förstl, H., Mösch, E., & Bickel, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106284 · Cited by 17
Park, M., Ahn, J., Lim, J., Han, M., Lee, J., Lee, J.-C., Hwang, S., & Kim, K. (2024) · Cells · doi:10.3390/cells13221920 · Cited by 16
“The risk of progression from MCI to AD dementia increases over time, with approximately 10% of individuals progressing within one year and 80% within six years following an MCI diagnosis [5–7].”
InfluentialUpdate on Major Neurocognitive Disorders
Jones, K. C. (2021) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20210004 · Cited by 21
The Vulnerability Index: A weighted measure of dementia and cognitive impairment risk
Kleiman, M. J., & Galvin, J. E. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12249 · Cited by 16
Zhang, Q., Coury, R., & Tang, W. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01421-y · Cited by 17
“Depending on the study population, about 10.2 to 33.6% MCI patients proceed to AD annually, while others either experience no further cognitive decline or return to normal cognition [2].”
BackgroundMethodInfluentialSORL1 Gene is Associated with the Conversion from Mild Cognitive Impairment to Alzheimer’s Disease
Piscopo, P., Tosto, G., Belli, C., Talarico, G., Galimberti, D., Gasparini, M., Canevelli, M., Poleggi, A., Crestini, A., Albani, D., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-141551 · Cited by 18
“: +39 06 49902930; +39 06 49902040; E-mail: annamaria.confaloni@iss.it. from 10.2 to 33.6% and from 9.8 to 36.3% over 2 years [2].”
InfluentialAlzheimer’s Disease and Other Dementias: An Introduction
Blank, R. H. (2018) · Springer eBooks · doi:10.1007/978-981-13-0656-3_1 · Cited by 18
Saunders, S., Ritchie, C. W., Russ, T. C., Terrera, G. M., & Milne, R. (2022) · BMC Geriatrics · doi:10.1186/s12877-021-02693-x · Cited by 18
“6%) [35], studies looking at longer term follo-ups concluded that most individuals with MCI had not converted to dementia at 4.”
BackgroundBandini, J. I., Schulson, L., Ahluwalia, S. C., Harrison, J. M., Chen, E. K., Lai, J., & Edelen, M. O. (2022) · Gerontology and Geriatric Medicine · doi:10.1177/23337214221131403 · Cited by 17
“CI is considered a risk factor for dementia (Moyer, 2014), and roughly one third of individuals with mild CI will develop Alzheimer’s dementia (Langa & Levine, 2014; Mitchell & Shiri-Feshki, 2009; Ward et al., 2013).”
BackgroundLargent, E. A., Lowers, J., Pope, T. M., Quill, T. E., & Wynia, M. K. (2024) · The Hastings Center Report · doi:10.1002/hast.1550 · Cited by 15
Yu, Q., Jiang, X., Yan, J., & Yu, H. (2024) · Geriatric Nursing · doi:10.1016/j.gerinurse.2024.05.018 · Cited by 15
Yang, C.-H., Wu, C.-H., Luo, K., Chang, H., Wu, S.-C., & Chuang, H. (2024) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2024.116885 · Cited by 15
Hsiao, Y.-T., Wu, C., Tsai, C.-F., Liu, Y., Trinh, T.-T., & Lee, C. (2021) · International Journal of Fuzzy Systems · doi:10.1007/s40815-021-01186-8 · Cited by 15
“Compared to healthy population, individuals with MCI have a much higher risk to develop into Alzheimer’s dementia [4].”
BackgroundGómez‐Soria, I., Ferreira, C., Oliván‐Blázquez, B., Aguilar‐Latorre, A., & Calatayud, E. (2023) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2023.104984 · Cited by 20
Li, J., Yang, M., Wei, R., Cao, Y., Xu, F., & Zhang, S. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231080 · Cited by 15
Sabbagh, M. N., Zhao, C., Mahendran, M., Jang, S. R., Laliberté, F., Toyosaki, H., Zhang, K., Frech, F. H., & Nair, K. V. (2025) · Neurology and Therapy · doi:10.1007/s40120-025-00756-4 · Cited by 14
“Between 12% and 18% of adults over 60 years of age in the USA are living with MCI [6], and approximately one-third of them will develop dementia within 5 years [7].”
Zhu, G., Zhang, C., Qin, X., Cao, W., Zheng, H., & Gao, J. (2021) · Journal of Functional Foods · doi:10.1016/j.jff.2021.104607 · Cited by 14
Huang, X., Zhang, S., Li, B., Zhao, X., Xu, J., Cao, T., & Wan, Q. (2022) · Geriatric Nursing · doi:10.1016/j.gerinurse.2022.03.010 · Cited by 14
Ikeda, C., Terada, S., Oshima, E., Hayashi, S., Okahisa, Y., Takaki, M., Inagaki, M., Yokota, O., & Uchitomi, Y. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2014.12.055 · Cited by 18
Siddiqui, T. G., Whitfield, T. J., Praharaju, J., Sadiq, D., Kazmi, H., Ben-Joseph, A., & Walker, Z. (2020) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000510951 · Cited by 13
Impaired Recognition of Facial and Vocal Emotions in Mild Cognitive Impairment
Moreira, H. S., Costa, A. S., Machado, Á., Castro, S. L., Vicente, S. G., & Lima, C. F. (2021) · Journal of the International Neuropsychological Society · doi:10.1017/s135561772100014x · Cited by 13
Bi, S., Yan, S., Chen, Z., Cui, B., Shan, Y., Yang, H., Qi, Z., Zhao, Z., Han, Y., & Lu, J. (2024) · EJNMMI Research · doi:10.1186/s13550-024-01068-8 · Cited by 13
“Approximately 16.5% of aMCI patients progress to AD annually [6].”
BackgroundInfluentialWang, Y., Li, M., Haughton, D., & Kazis, L. E. (2024) · PLoS ONE · doi:10.1371/journal.pone.0306270 · Cited by 14
Revolutionizing Alzheimer’s Diagnosis and Management: The Dawn of Biomarker-Based Precision Medicine
Kwon, H. S., Yu, H., & Koh, S. (2024) · Dementia and Neurocognitive Disorders · doi:10.12779/dnd.2024.23.4.188 · Cited by 16
“21 This slow progression rate presents a critical challenge to demonstrating the efficacy of a potential drug.”
BackgroundTao, W., Li, H., Li, X., Huang, R., Shao, W., Guan, Q., & Zhang, Z. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.687530 · Cited by 11
“In particular, about one-third of those with amnesiac mild cognitive impairment (aMCI) will develop AD within 5 years (Ward et al., 2013).”
BackgroundDiagnostic Accuracy of the Five-Word Test for Mild Cognitive Impairment Due to Alzheimer’s Disease
Fornari, C., Mori, F., Zoppi, N., Libri, I., Silvestri, C., Cosseddu, M., Turrone, R., Maffi, M., Caratozzolo, S., Borroni, B., et al. (2022) · Neurology International · doi:10.3390/neurolint14020029 · Cited by 11
“The prevalence of people over 65 years old with MCI ranges from 10% to 20% [8], and about 15% of those with MCI develop dementia after two years [9], while about 32% of patients with MCI develop dementia within five years [10].”
BackgroundNeuroanatomical Correlates of Cognitive Tests in Young-onset MCI
Carbone, C., Balboni, E., Beltrami, D., Gasparini, F., Vinceti, G., Gallingani, C., Salvatori, D., Salemme, S., Molinari, M. A., Tondelli, M., et al. (2023) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2206152 · Cited by 9
“Mild Cognitive Impairment (MCI), characterised by cognitive changes that do not affect everyday functioning, can be a transitional stage in the continuum from normal aging to dementia, and it is frequently considered a prede-mentia phase of Alzheimer’s Dementia (AD) [1].”
BackgroundMonoclonal antibodies for treating early Alzheimer disease—a commentary on recent ‘positive’ trials
Scott, I. A. (2024) · Age and Ageing · doi:10.1093/ageing/afae023 · Cited by 12
Gustavsson, E., Raaschou, P., Lärfars, G., Sandman, L., & Juth, N. (2021) · Journal of Medical Ethics · doi:10.1136/medethics-2021-107304 · Cited by 11
“5 However, from this perspective, the preclinical and the MCI phase constitute a ‘ther-apeutic window’ when drugs could slow down the development of the disease, for example, by reducing the amyloid burden or tau pathology.”
Amos, J. G., Zheng, L., Eramudugolla, R., Parekh, D., Huque, M. H., Delbaere, K., Lautenschlager, N. T., & Anstey, K. J. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-075015 · Cited by 12
Wang, P., Sun, W., Gong, J., Han, X., Xu, C., Chen, Y., Yang, Y., Luan, H., Li, S., Li, R., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-082404 · Cited by 12
“12 Consequently, early intervention in the symptomatic predementia phase of AD holds the potential to delay or even reverse cognitive deterioration.”
Background
Metadata
- Authors
- Ward, A., Tardiff, S., Dye, C., & Arrighi, H. M.
- Affiliations
- Janssen Alzheimer Immunotherapy Research & Development (United States) (US)
- Corresponding author
- Arrighi, H. Michael
- ORCID
- Ward, Alex
- Venue
- Dementia and Geriatric Cognitive Disorders Extra
- Publisher
- S. Karger AG
- Published
- 2013-09-28
- Volume
- 3
- Issue
- 1
- Pages
- 320-332
- ISSN
- 1664-5464 (ISSN-L)
- PMC
- PMC3808216
- OpenAlex
- W2010643121
- Cited by
- 426
- References
- 68
- Citations by year
- 2026: 28 · 2025: 47 · 2024: 64 · 2023: 61 · 2022: 44 · 2021: 60 · 2020: 32 · 2019: 30 · 2018: 26 · 2017: 5 · 2016: 14 · 2015: 11 · 2014: 4
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/3.0/ (vor)
- creativecommons.org/licenses/by-nc/3.0/ (tdm)
- Locations
- Dementia and Geriatric Cognitive Disorders Extra (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- prodromal Alzheimer's disease, Alzheimer's dementia, conversion rate, mild cognitive impairment, amnestic mild cognitive impairment, cohort studies, loss to follow-up, diagnostic criteria
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
